Tecentriq (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs)
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
Medicine name |
Tecentriq
|
Active substance |
atezolizumab
|
Therapeutic area (MeSH) |
|
Procedure number |
EMEA/H/C/00414/II/0054
|
Regulatory outcome |
Variation
|
DHPC type |
Adverse event
|
Human ATC code |
L01FX
|
Dissemination date |
25/03/2021
|